Luspaterecpt before epoetin in low grade MDS patients.
Pembrolizumab in lymphoma, this is not a common one, usually in young females, could be hard to treat.
For our radiation oncology colleagues, any comments? For oligometastases, radiation therapy helps improve survival when added to systemic therapy.
Combination PARP with androgen blocker, regardless of HRR gene alterations showed benefit vs. androgen blocker alone.
High burden prostate cancer patients benefit form androgen deprivation and Taxotere combination.
CAR-T for second line is better than standard of care, the question is: how about compared to BITE therapy? Future is exciting for those patients.
Paradigm shift in rectal cancer therapy? Some may not need surgery, now some may not need radiotherapy.
Retrospective review showing equivocal outcomes in cT2-T4N0 patients treated with radical cystectomy vs TURBT + chemoradiation. There were similar rates of neoadjuvant chemotherapy being given in both groups. Based on prospective data, the SOC remains cisplatin-based neoadjuvant chemo followed by radical cystectomy; however, trimodality therapy may not have worse outcomes, and it would be great to see a prospective head-to-head study.
Benign heme article of the month– A significant portion of patients with stable platelet counts can be gently tapered from TPO-agonists. Those who needed to be re-challenged had a good response. This is likely an underutilized strategy.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
